DB-102 Drug Insight

“DB-102 Market Size, Forecast, and Emerging Insight – 2032” report offers an in-depth analysis of both market and emerging insights regarding DB-102 for the treatment of Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the DB-102 in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the DB-102. The DB-102 market report provides insights into the DB-102 moa, dosage, administration, research, and development, including regulatory milestones and other developmental activities. Further, it also consists of future market assessments inclusive of the DB-102 market forecast analysis in the 7MM, SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about other emerging therapies in Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM).

DB-102 Drug Summary

Enzastaurin (DB-102) is an oral drug manufactured by Denovo Biopharma: The hydrochloride salt of enzastaurin, a synthetic macrocyclic bisindolemaleimide with potential antineoplastic activity. Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden.

Despite numerous attempts by many drug companies, Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM)  remain one of the deadliest cancers, and the first-line drug treatment still relies on temozolomide as the backbone. Many promising anticancer drugs, including anti-PD-1 drugs, failed to surpass temozolomide’s efficacy. With Denovo’s newly discovered DGM1 biomarker, it was found that the addition of enzastaurin may improve outcomes in Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM) patients who possess the DGM1 biomarker and are exposed to a high dose of DB102, regardless of MGMT methylation status. Denovo plans to conduct a randomized, double-blind, placebo-controlled Phase III pivotal study of enzastaurin in combination with temozolomide during and following radiation therapy in newly diagnosed Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM) patients. DB-102 is currently being evaluated under Phase III clinical trials for treating patients suffering from Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM).

Scope of the DB-102 Market Report

The DB-102 market report provides insights into:

• A comprehensive product overview including the DB-102 description, DB-102 moa, dosage and administration, research and development activities in Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM).
• Elaborated details on DB-102 regulatory milestones and other development activities have been provided in this report.
• The DB-102 market report also highlights the DB-102 research and development activities in Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM) across the United States, Europe, and Japan.
• The DB-102 market report also covers the patent information with an expiry timeline around DB-102.
• The DB-102 market report contains forecasted DB-102 sales for Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM).
• The DB-102 market report also features the SWOT analysis with analyst views for DB-102 in Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM).

DB-102 Methodology

The DB-102 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DB-102 Analytical Perspective by DelveInsight

• In-depth DB-102 Market Assessment

This DB-102 market report provides a detailed market assessment of DB-102 for Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted DB-102 sales data from 2026 to 2032.

• DB-102 Clinical Assessment

The DB-102 market report provides the clinical trials information of DB-102 for Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM) covering trial interventions, trial conditions, trial status, start and completion dates.

DB-102 Market Report Highlights 

• In the coming years, the market scenario for Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the DB-102 manufacturers to penetrate more into the market.  
• The DB-102 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DB-102 dominance.
• Other emerging products for Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM) are expected to give tough market competition to DB-102, and the launch of late-stage emerging therapies in the near future will significantly impact the DB-102 market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of DB-102 in Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM).
• Analyze DB-102 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted DB-102 sales data from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DB-102 in Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM).

Key Questions

• What is the product type, route of administration, and mechanism of action of DB-102?
• What is the DB-102 clinical trial status of the studies related to Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM), and what is the study completion date?
• What are the key collaborations, mergers and acquisitions, licensing, and other activities related to the DB-102 development?
• What are the key designations that have been granted to DB-102 for Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM)?
• What is the forecasted market scenario of DB-102 for Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM)?
• What are the forecasted DB-102 sales in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available, and how are these competing with DB-102 for diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM)?
• Which are the late-stage emerging therapies under development for the treatment of Diffuse large B-cell lymphoma (DLBCL) and glioblastoma multiforme (GBM)?